Publication
Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study
Ulrich Laufs, Andreas L. Birkenfeld, Uwe Fraass, Bernd Hohenstein, Carsten Siegert, Jens Klotsche, Elisabeth Steinhagen-Thiessen, David Pittrow, Stefan Dexl, Sunnhild Salmen, Volker J. J. Schettler, Klaus G. Parhofer, Sebastian Noé, Ulrike Spengler, Franz-Rudolf Fendler, Anselm Bäumer, Norbert Schön, Tilman Unger, Jens Taggeselle, Andreas Schwittay, Ulf Janseen, Frank Menzel, Christoph Axthelm, Andreas Wilke, Antje Spens, Ayham Al-Zoebi, Volker J.J. Schettler, Toralf Schwarz, Armin Jansen, Bernd Hohenstein, Alexander Stadelmann, Karin Eberhand, Katrin Borucki, Elisabeth Steinhagen-Thiessen, Axel Schlitt, Markus Knittel, Ann-Cathrin Koschker, Alexander Mann, Hans-Holger Ebert, Mohsen Tekiyeh, Katrin Gebauer, Ralf Spitthöver, Andrea Beigel, Ulrich Laufs, David Sinning, Norbert Jahnke, Beate Wild, Detlef Gysan, Johannes Ruef, Matthias Weißbrodt, Andreas Birkenfeld, Holger Killat, Steffen Bischoff, Johannes Beckermann, Ina Wittig, Jens Gerth, Peter Salbach, Dirk Raddatz, Wolfgang Ries, Markolf Hanefeld, Johannes Haas, Ilka Simon-Wager, Christian Zugck, Thomas Twisselmann, Volker Neumann, Markus Brode, Jens Ringel, Beate Schulze, Hansjörg Rothe, Wolfram Oettler, Alexander Stöckl, Sven Meyer, Sebastian Keßler, Rüdiger Meesters, Michael Brandt, Ksenija Stach-Jablonski, Berthold Amann
Cardiovascular Drugs and Therapy, September 2022, Springer Science + Business Media
DOI: 10.1007/s10557-022-07386-0